Opko Health, Inc. (NASDAQ:OPK) has received a consensus recommendation of “Hold” from the eleven ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $14.81.

A number of equities analysts have commented on OPK shares. BidaskClub downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Jefferies Group LLC reaffirmed a “hold” rating and set a $6.50 target price (down from $6.80) on shares of Opko Health in a research note on Thursday, August 10th. Zacks Investment Research downgraded shares of Opko Health from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. Cantor Fitzgerald started coverage on shares of Opko Health in a research note on Thursday, August 17th. They set an “overweight” rating and a $20.00 target price on the stock. Finally, J P Morgan Chase & Co downgraded shares of Opko Health from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $12.00 to $7.00 in a research note on Thursday, September 14th.

Opko Health (OPK) traded up $0.21 during trading hours on Thursday, hitting $5.01. 2,720,000 shares of the stock traded hands, compared to its average volume of 5,369,291. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01. Opko Health has a 12-month low of $4.50 and a 12-month high of $12.15.

Opko Health (NASDAQ:OPK) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The firm had revenue of $263.50 million for the quarter, compared to analysts’ expectations of $319.43 million. During the same period last year, the firm earned ($0.03) earnings per share. Opko Health’s revenue for the quarter was down 11.6% on a year-over-year basis. research analysts anticipate that Opko Health will post -0.27 earnings per share for the current year.

In related news, CEO Phillip Md Et Al Frost purchased 80,000 shares of Opko Health stock in a transaction dated Friday, September 15th. The shares were acquired at an average cost of $6.01 per share, with a total value of $480,800.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $18,444,395.51. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Opko Health, Inc. purchased 655,738 shares of Opko Health stock in a transaction dated Monday, October 30th. The stock was bought at an average cost of $3.05 per share, for a total transaction of $2,000,000.90. Following the completion of the purchase, the insider now directly owns 6,678,752 shares in the company, valued at approximately $20,370,193.60. The disclosure for this purchase can be found here. Insiders bought a total of 1,052,238 shares of company stock worth $4,374,796 over the last three months. Insiders own 40.19% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Opko Health by 1.1% in the second quarter. Vanguard Group Inc. now owns 26,618,758 shares of the biotechnology company’s stock valued at $175,151,000 after purchasing an additional 296,757 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Opko Health by 1.1% in the second quarter. BlackRock Inc. now owns 22,901,261 shares of the biotechnology company’s stock valued at $150,689,000 after purchasing an additional 255,976 shares in the last quarter. State Street Corp grew its holdings in shares of Opko Health by 3.9% in the second quarter. State Street Corp now owns 11,348,763 shares of the biotechnology company’s stock valued at $74,671,000 after purchasing an additional 422,203 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Opko Health by 127.2% in the third quarter. Dimensional Fund Advisors LP now owns 4,003,643 shares of the biotechnology company’s stock valued at $27,466,000 after purchasing an additional 2,241,103 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Opko Health by 83.7% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,579,950 shares of the biotechnology company’s stock valued at $17,698,000 after purchasing an additional 1,175,726 shares in the last quarter. Hedge funds and other institutional investors own 22.33% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Brokerages Set Opko Health, Inc. (OPK) Target Price at $14.81” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/brokerages-set-opko-health-inc-opk-target-price-at-14-81/1727998.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Analyst Recommendations for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.